Participated · Series B · Jan 2022

Wellster operates a Munich-based telemedicine platform providing drug-based and digital therapies across categories including mental health, medical self-tests, erectile dysfunction (via sister brand Spring), and hair-loss treatments at myspring.com. The company was founded in 2018 and follows a replication strategy modeled on U.S. DTC health players such as Hims & Hers and Roman. In addition to existing services, Wellster plans to use new capital to launch a dedicated femtech platform offering treatments for intimate and lifestyle health concerns. Financially, the firm completed an initial $40 million injection six months ago and has now added a $20 million Series B extension; to date the platform has attracted $61.7 million in funding. Wellster emphasizes its European roots and regulatory experience as advantages against non‑European entrants. The company sells diagnosis-led medication delivery through partner pharmacies or direct shipment to patients following online consultations. Wellster, founded in 2018 and based in Munich/Bavaria, provides drug-based and digital therapy treatments. Its offerings include mental health services and medical self-tests, and it has launched a sister brand, Spring, which serves as a grey market for ED pills at gospring.de and for hair-loss products at myspring.com. The company says it is replicating business models that succeeded in the U.S., citing Hims & Hers and Roman as templates. Co-founder Dr. Manuel Nothelfer said the funding round "cements our ambition to expand our offering to more target groups in the future, improving the personalized healthcare services." Wellster frames its approach as focused on tailored drug-based and digital therapies rather than technological innovation. The company raised $40 million in a round led by Dermapharm with support from existing investors HV Capital and SevenVentures.